Quarterly report pursuant to Section 13 or 15(d)

Related Party Transactions (Tables)

v3.3.0.814
Related Party Transactions (Tables)
9 Months Ended
Sep. 30, 2015
Related Party Transactions [Abstract]  
Summary of activities related to related party

 

Milestones   Payments  
       
(1) filing of an New Drug Application (“NDA”) or regulatory approval for each licensed product   $ 750,000  
(2) upon the receipt of regulatory approval from the U.S. FDA for each licensed product     1,750,000